stability guidance -draft
...of drug substance placed on stability should be representative of both the quality of the.....this guidance to mean a batch of drug substance or drug product manufactured at the scale.....compromise the quality, purity, or stability of the drug substance and the resulting drug..
http://www.fda.gov/cder/guidance/1707dft.pdf (score=100)
MDI and DPI Drug Products
...establish a set of criteria to which a drug substance or drug product should conform using.....manufacturing, processing, packaging, controls, stability testing, or labeling operations.....of each facility involved in the manufacturing of the drug substance and excipients should..
http://www.fda.gov/cder/guidance/2180dft.pdf (score=86)
Guidance- Content & Format CMC for Vaccine & Related Product
...A list should be provided of all components in the drug product, including drug substance(s)and other ingredients, with.....This section should contain information on the stability of the drug substance and any in.....material at each holding step, as outlined in "Stability Testing of New Drug Substances..
http://www.fda.gov/cber/gdlns/cmcvacc.pdf (score=73)
WAIS Document Retrieval
...Such studies should normally be conducted on the drug product or drug substance containing the degradation.....Degradation products observed in stability studies conducted at recommended storage.....Safety studies should provide a comparison of results of safety testing of the drug product or drug substance..
http://www.fda.gov/cder/guidance/ichq3b.htm (score=68)
þÿ
...2 This guidance has been prepared by Drug Substance Technical Subcommittee of the Chemistry.....should explain the scientific reasons why a stability indicating procedure is not viable.....drug substance information to support NADAs and ANADAs can be formatted according to the CTD-Q..
http://www.fda.gov/cder/guidance/3969DFT.pdf (score=66)
þÿ
...2 This guidance has been prepared by Drug Substance Technical Subcommittee of the Chemistry.....should explain the scientific reasons why a stability indicating procedure is not viable.....drug substance information to support NADAs and ANADAs can be formatted according to the CTD-Q..
http://www.fda.gov/OHRMS/DOCKETS/98fr/2003d-0571-gdl0001.pdf (score=64)
FDA Concept Paper: Drug Products That Present Demonstrable Difficulties for...
...A vehicle that optimally delivers one drug substance may be inappropriate for delivery of a.....Factors such as drug stability in the vehicle, the specific product use, and the site of.....Skin temperature and moisture also influence the rate and extent of absorption of the drug..
http://www.fda.gov/cder/fdama/difconc.htm (score=63)
...Stability-indicating analytical methods should be developed to monitor the stability of the drug substance and.....The stability of a botanical drug substance or product generally should not be based entirely on the assay of the active.....These regulations require documentation of the drug substance, drug product, placebo, labeling..
http://www.fda.gov/cder/guidance/4592fnl.doc (score=63)
Substance
...individual batches of the drug substance used in animal and clinical testing, Drug Substance.....Stability.. The regulations require a full description of the stability of the drug.....the subsequent bioavailability and stability requirements of the final dosage form. II..
http://www.fda.gov/cder/guidance/drugsub.pdf (score=61)
Guidance for Industry: Monoclonal Antibodies Used as Reagents in Drug...
...2 The term drug substance, which is used throughout the text, is intended to include biological.....The mAb manufacturer should perform real-time stability studies of unconjugated and.....the potential impact on the biological safety, quality, and purity of the drug substance and/or..
http://www.fda.gov/cber/gdlns/mab032901.pdf (score=56)
Chem Revs. of DMFs for DSIs
...Summarize the data showing that the container/closure system is compatible with the drug.....If a stability-indicating test is used which is different from the release test, this.....the bioavailability of the drug products made from the substance, including, for example,specifications relating to..
http://www.fda.gov/cder/mapp/5015-4.pdf (score=54)
Content and Format of INDs for Phase 1 Studies of Drugs, Inclu
...Food and Drug Administration, Center for Drug Evaluation and Research,"IND Process and.....Information to support the stability of the drug..substance during the toxicologic studies.....Information to support the stability of the drug..substance during the toxicologic studies..
http://www.fda.gov/cder/guidance/clin2.pdf (score=49)
IND content and format for Phase 1 studies
...As clinical development of a drug product proceeds,sponsors should discuss the.....Information to support the stability of the drug..substance during the toxicologic studies.....Information to support the stability of the drug..substance during the toxicologic studies..
http://www.fda.gov/cder/guidance/phase1.pdf (score=47)
Definition of Identity Polymorphism
...Over the years FDA has approved many generic drug products based upon a drug substance with different physical form from.....For an enantiotropic system, the relative stability of a pair of solid forms inverts at.....Polymorphism is often characterized as the ability of a drug substance to exist as two or more..
http://www.fda.gov/ohrms/dockets/ac/02/briefing/3900B1_04_Polymorphism.htm (score=47)
GUIDE TO INSPECTIONS OF ORAL SOLID DOSAGE FORMS PRE/POST APPROVAL ISSUES...
...For example, micronizing or milling a drug substance and providing greater surface area of the.....The Center for Drugs conducts an evaluation of the stability data and approves the.....Characterization of the chemical and physical properties of the drug substance is one of the..
http://www.fda.gov/ora/inspect_ref/igs/solid.html (score=44)
Validation of Chromatographic Methods
...with the regulatory impurities method relating to release and stability of..both drug substance and drug product.....Solution stability of the drug substance or drug product after preparation..according to the test method should be evaluated.....Data that are generated for acceptance,release, stability, or pharmacokinetics will only..
http://www.fda.gov/cder/guidance/cmc3.pdf (score=42)
Microsoft Word - 5320.1.doc
...process and validation information for a sterile drug substance is the same as..for a sterile.....2 Post-Approval Stability Protocol and Stability Commitment.. Analytical procedures and testing schedule for.....6 ONLY if the drug substance is sterile or if..other product quality microbiology issues are..
http://www.fda.gov/cder/mapp/5320.1.pdf (score=42)
Microsoft Word - 5020.1.doc
...process and validation information for a sterile drug substance is the same as..for a sterile.....2 Post-Approval Stability Protocol and Stability Commitment.. Analytical procedures and testing schedule for.....6 ONLY if the drug substance is sterile or if..other product quality microbiology issues are..
http://www.fda.gov/cder/mapp/5020.1.pdf (score=42)
...1 Influence on Manufacturing of the Drug Product Drug substance polymorphic forms can also exhibit different.....The extent of conversion generally depends on the relative stability of the polymorphs.....For example, in one approved drug product, the drug substance can exist in at least twenty polymorphic forms, but..
http://www.fda.gov/cder/guidance/6154dft.doc (score=39)
Q1B Photostability Testing of New Drug Substances and Products
...This testing may involve the drug substance alone and/or in simple solutions/suspensions to.....The ICH Harmonized Tripartite Guideline on Stability Testing of New Drug Substances and.....Normally, only one batch of drug substance is tested during the development phase, and then the..
http://www.fda.gov/cder/guidance/1318.htm (score=35)
Powered by viXML, providing custom search results
Las Vegas Injury Lawyer
